Using Magnetic Resonance Imaging to Predict People Who Are Likely to

Status Completed

Clinical Trial Summary

Flash pulmonary edema is a sudden, abnormal build-up of fluid in the lungs. It is usually caused by heart failure and can be life threatening. The purpose of this study is to determine if a new form of magnetic resonance imaging (MRI) can identify abnormal blood flow to the lungs and predict increased risk of developing flash pulmonary edema among older adults.

Clinical Trial Description

Pulmonary edema is a condition in which an abnormal build-up of fluid occurs in the lungs, which then leads to swelling. Symptoms include shortness of breath, breathing difficulty, and coughing. Flash pulmonary edema, which develops suddenly and can be life-threatening, is usually caused by heart failure. It occurs when the left ventricle of the heart is weakened and does not function properly, potentially impeding the flow of blood from the heart to the rest of the body. Blood pressure and fluid volume then increase, and excess blood accumulates in the blood vessels and tissues of the lungs. Flash pulmonary edema requires immediate treatment, including supplemental oxygen, mechanical ventilation, or medication. This study will determine if a new form of MRI testing can be used to identify probable abnormalities in blood flow to the lungs and predict increased risk of developing flash pulmonary edema among older adults. This study will enroll people who are at risk of developing flash pulmonary edema. At a baseline study visit, participants will undergo a medical record review, a physical exam, blood collection, questions about cardiovascular health, and an MRI stress test. For the stress test, participants will first receive the medication dobutamine, which will increase their heart rate and reduce the blood supply to their heart. Participants will then be placed in an MRI machine and images of their heart will be taken. All participants will complete follow-up cardiovascular health questionnaires three times a year for 1 to 10 years, depending on when participants are enrolled into the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00542503
Study type	Observational
Source	Wake Forest University Health Sciences
Contact
Status	Completed
Phase
Start date	June 1, 2007
Completion date	December 1, 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01357850` - A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure	Phase 2
Recruiting	`NCT00532688` - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure	Phase 2/Phase 3
Terminated	`NCT00383630` - Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure	Phase 2
Completed	`NCT00531661` - CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients	N/A
Completed	`NCT00149435` - Cardiovascular Health Study (CHS) Events Follow-up Study
Completed	`NCT00159614` - Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment	Phase 2
Completed	`NCT00241761` - Epidemiology of Depression and Heart Failure in Aging	N/A
Terminated	`NCT00125437` - Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy	N/A
Terminated	`NCT00357591` - Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation	N/A
Completed	`NCT00202579` - Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure	Phase 2
Completed	`NCT00094263` - Long-Term Predictors of Morbidity in Older Age	N/A
Completed	`NCT00048425` - Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.	Phase 3
Completed	`NCT00530426` - Heart Failure Registry	Phase 4
Completed	`NCT00023556` - Genetic Architecture of Heart Disease in Rural Brazil	N/A
Terminated	`NCT00190359` - Growth Hormone and Heart Failure	N/A
Completed	`NCT00004562` - Occluded Artery Trial (OAT)	Phase 3
Completed	`NCT00005265` - Natural History of Coronary Heart Disease	N/A
Completed	`NCT02772068` - Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a	Early Phase 1
Completed	`NCT02925546` - A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets	Phase 1
Completed	`NCT01074307` - A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Using Magnetic Resonance Imaging to Predict People Who Are Likely to Develop Flash Pulmonary Edema (The PREDICT Study) — PREDICT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms